PAVM - PAVmed Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

PAVmed Inc.

One Grand Central Place
Suite 4600
New York, NY 10165
United States

IndustryMedical Devices
Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Dr. Lishan Aklog M.D.Chairman & CEO636.5kN/A1966
Mr. Dennis M. McGrath CPAPres, CFO & Sec.561.75kN/A1957
Dr. Brian J. deGuzman M.D.Chief Medical Officer414.5kN/A1965
Mike HavrillaDirector of Investor RelationsN/AN/AN/A
Mr. Shaun M. O'NeilChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

Corporate Governance

PAVmed Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.